Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allogeneic adipose-derived mesenchymal stromal cells for critically ill COVID-19 patients
2020-001266-11Phase 2Terminated
- Sponsor
- Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz
- Start
- Apr 2020
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised trial of allogeneic adipose-derived mesenchymal stromal cells in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz. Primary endpoint: 28-day survival. Started Apr 2020; status: terminated.
02
Drugs
allogeneic adipose-derived mesenchymal stromal cells
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2020-001266-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001266-11.